Compare Becton Dickinson and Co (BDX) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $107.03. The key difference: Becton Dickinson and Co pays a 2.79% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| BDX | LQD | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | — |
52-Week High | $185.39 | $112.91 |
52-Week Low | $135.49 | $106.96 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, trades at $106.96, down 0.47% on the day. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators suggest potential oversold conditions. Recent dividend payouts of $0.38-$0.42 per share highlight its income focus. Fixed income ETFs are gaining investor attention amid economic resilience and rate uncertainty, with bond inflows surging 60% year-over-year as of June 2026 (CNBC, 2026-06-25).
Outlook: LQD offers exposure to investment-grade corporate bonds with steady dividends, but faces headwinds from potential Fed rate hikes and inflation concerns. Risks include interest rate sensitivity and narrowing market breadth. Analyst comparisons favor LQD for lower drawdowns versus peers, but investors should weigh yield against Treasury alternatives. The ETF's performance hinges on macroeconomic policy shifts and corporate debt market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
